Literature DB >> 3883167

Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer.

B Fisher, M Bauer, R Margolese, R Poisson, Y Pilch, C Redmond, E Fisher, N Wolmark, M Deutsch, E Montague.   

Abstract

In 1976 we began a randomized trial to evaluate breast conservation by a segmental mastectomy in the treatment of Stage I and II breast tumors less than or equal to 4 cm in size. The operation removes only sufficient tissue to ensure that margins of resected specimens are free of tumor. Women were randomly assigned to total mastectomy, segmental mastectomy alone, or segmental mastectomy followed by breast irradiation. All patients had axillary dissections, and patients with positive nodes received chemotherapy. Life-table estimates based on data from 1843 women indicated that treatment by segmental mastectomy, with or without breast irradiation, resulted in disease-free, distant-disease-free, and overall survival at five years that was no worse than that after total breast removal. In fact, disease-free survival after segmental mastectomy plus radiation was better than disease-free survival after total mastectomy (P = 0.04), and overall survival after segmental mastectomy, with or without radiation, was better than overall survival after total mastectomy (P = 0.07, and 0.06, respectively). A total of 92.3 per cent of women treated with radiation remained free of breast tumor at five years, as compared with 72.1 per cent of those receiving no radiation (P less than 0.001). Among patients with positive nodes 97.9 per cent of women treated with radiation and 63.8 per cent of those receiving no radiation remained tumor-free (P less than 0.001), although both groups received chemotherapy. We conclude that segmental mastectomy, followed by breast irradiation in all patients and adjuvant chemotherapy in women with positive nodes, is appropriate therapy for Stage I and II breast tumors less than or equal to 4 cm, provided that margins of resected specimens are free of tumor.

Entities:  

Mesh:

Year:  1985        PMID: 3883167     DOI: 10.1056/NEJM198503143121101

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  264 in total

1.  Recent Progress in Breast Conserving Therapy: From Experiences in Japan.

Authors: 
Journal:  Breast Cancer       Date:  1996-12-20       Impact factor: 4.239

2.  Is mastectomy overused? A call for an expanded research agenda.

Authors:  Paula V Lantz; Judith K Zemencuk; Steven J Katz
Journal:  Health Serv Res       Date:  2002-04       Impact factor: 3.402

3.  Management of breast cancer: what do I tell the patient?

Authors:  C J Wright
Journal:  Can Fam Physician       Date:  1986-01       Impact factor: 3.275

4.  Local Recurrence after Conservative Surgery for Breast Cancer.

Authors: 
Journal:  Breast Cancer       Date:  1996-06-28       Impact factor: 4.239

5.  The Impacts of Breast Conserving Treatment and Mastectomy on the Quality of Life in Early-stage Breast Cancer Patients.

Authors: 
Journal:  Breast Cancer       Date:  1995-04-30       Impact factor: 4.239

6.  Controversies in the Surgical Management of Operable Breast Cancer.

Authors: 
Journal:  Breast Cancer       Date:  1994-12-30       Impact factor: 4.239

Review 7.  Choosing quality of care measures based on the expected impact of improved care on health.

Authors:  A L Siu; E A McGlynn; H Morgenstern; M H Beers; D M Carlisle; E B Keeler; J Beloff; K Curtin; J Leaning; B C Perry
Journal:  Health Serv Res       Date:  1992-12       Impact factor: 3.402

8.  Nipple-sparing mastectomies: Clinical outcomes from a single academic institution.

Authors:  Barbara Dull; Leah Conant; Terence Myckatyn; Marissa Tenenbaum; Amy Cyr; Julie A Margenthaler
Journal:  Mol Clin Oncol       Date:  2017-04-04

9.  Variation in breast cancer surgery in Ontario.

Authors:  N A Iscoe; V Goel; K Wu; G Fehringer; E J Holowaty; C D Naylor
Journal:  CMAJ       Date:  1994-02-01       Impact factor: 8.262

Review 10.  Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy.

Authors:  G L Plosker; D Faulds
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.